850449-93-3

Basic information

• Product Name: METHYL 2-(5-AMINO-2-METHYLPHENYL)ACETATE
• Synonyms: BENZENEACETIC ACID, 5-AMINO-2-METHYL-, METHYL ESTER;METHYL 2-(5-AMINO-2-METHYLPHENYL)ACETATE;2-(5-aMino-2-Methylphenyl)propanoate
• CAS NO: 850449-93-3
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.218
• Mol File: 850449-93-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 298.288 °C at 760 mmHg
• Flash Point: 154.154 °C
• Appearance: /
• Density: 1.115 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: METHYL 2-(5-AMINO-2-METHYLPHENYL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-(5-AMINO-2-METHYLPHENYL)ACETATE(850449-93-3)
• EPA Substance Registry System: METHYL 2-(5-AMINO-2-METHYLPHENYL)ACETATE(850449-93-3)

Safety Data

• Hazardous Substances Data: 850449-93-3(Hazardous Substances Data)

Usage

General Description

Methyl 2-(5-amino-2-methylphenyl)acetate is a chemical compound with the molecular formula C10H13NO2. It is a methyl ester derivative of 5-amino-2-methylphenylacetic acid and is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. METHYL 2-(5-AMINO-2-METHYLPHENYL)ACETATE has potential applications in medicinal chemistry and drug discovery due to its ability to modify the bioactivity of certain molecules. It is important to handle and store this chemical with caution, as it may pose health and safety risks if not used properly.

InChI:InChI=1/C10H13NO2/c1-7-3-4-9(11)5-8(7)6-10(12)13-2/h3-5H,6,11H2,1-2H3

Upstream product

• 1975-52-6 5-nitro-o-toluic acid 
• 22474-47-1 (2-methyl-5-nitro-7-phenyl)methanol 
• 409082-10-6 (2-methyl-5-nitrophenyl)-methyl methylsulfonate 
• 409082-11-7 2-(2-methyl-5-nitrophenyl)acetonitrile 
• 287119-83-9 2-(2-Methyl-5-nitrophenyl)acetic acid 
• 644-36-0 o-methylphenylacetic acid 
• 287119-84-0 2-methyl-5-nitrophenylacetic acid methyl ester 

Downstream Products

• 287119-90-8 methyl 2-methyl-5-(N-methylamino)phenylacetate 
• 287120-02-9 methyl 2-methyl-5-[N-methyl-N-(tert-butyloxycarbonyl)]aminophenylacetate 
• 287120-06-3 2-methyl-5-[N-methyl-N-(tert-butyloxycarbonyl)]aminophenylacetic acid 
• 287120-10-9 N-[2-(N,N-dimethylamino)ethyl]-2-methyl-5-[N-methyl-N-(tert-butyloxycarbonyl)]aminophenylacetamide 
• 287119-98-6 2-methyl-5-[N-methyl-N-(4-nitrobenzyloxycarbonyl)]aminophenylacetic acid 
• 287119-94-2 methyl 2-methyl-5-[N-methyl-N-(4-nitrobenzyloxycarbonyl)]aminophenylacetate 
• 850451-77-3 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one 
• 1021535-32-9 3-(5-amino-2-methyl-phenyl)-7-chloro-1-phenyl-1H-[1,6]naphthyridin-2-one 
• 850450-21-4 N-(4-methyl-3-{1-methyl-7-[3-(4-methyl-piperazin-1-y)-phenylamino]-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl}-phenyl)-3-trifluoromethyl-benzamide 
• 850450-20-3 N-{3-[7-(3-dimethylaminomethyl-phenylamino)-1-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl]-4-methyl-phenyl}-3-trifluoromethyl-benzamide 
• 850450-17-8 N-{3-[7-(6-methoxy-pyridin-3-ylamino)-1-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl]-4-methyl-phenyl}-3-trifluoromethyl-benzamide 
• 850451-23-9 N-[3-(7-benzylamino-1-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl)-4-methyl-phenyl]-3-trifluoromethyl-benzamide 
• 850450-18-9 N-[3-(7-ethylamino-1-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl)-4-methyl-phenyl]3-trifluoromethyl-benzamide 
• 850450-22-5 N-[3-(7-amino-1-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl)-4-methyl-phenyl]-3-trifluoromethyl-benzamide 

Relevant articles and documents

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

RORGAMMA MODULATORS AND USES THEREOF

The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR , PDGFR , CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF , SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2 , BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.